In a recent study of Italian specialized centers on diabetes care, only 26.8% of T2DM patients at high CV risk were treated with high-intensity statin therapy, only 3.9% with GLP1-RA and only 2.8% with SGLT2-i. This evidence concerns the gene GLP1R and diabetes mellitus.